Journals listed in Web of Science and JCR receive many submissions and desk reject a large share. A section-by-section audit by a PhD reviewer in your area shows what to fix first.
Manuscript Auditing →01Impact factor
Impact factor of Journal of Immunotherapy (2026)
The impact factor shown here is the 2-year mean citedness: citations received in a year by the papers Journal of Immunotherapy published in the two previous years, divided by the number of those papers. That is the same formula as the Journal Impact Factor, applied to the open citation data of OpenAlex. The journal is listed in JCR 2024, so it also has an official Journal Impact Factor published by Clarivate, which can differ because it counts citations from Web of Science journals only.
Rank in its subject categories
- Oncologyrank 184 of 347 journals
- Medicine, Research & Experimentalrank 111 of 203 journals
- Immunologyrank 121 of 189 journals
Ranks here compare journals of the same Web of Science category in our data by 2-year citedness; they are not the official JCR rank.
Quartile of Journal of Immunotherapy
A journal's quartile (Q1 to Q4) is its position within a subject category: Q1 is the top quarter. The official quartiles are published by Clarivate in Journal Citation Reports (by Journal Impact Factor, in Web of Science categories) and by Scimago as the SJR quartile (in Scopus categories). Journal of Immunotherapy is listed in JCR 2024, so its JCR quartile is in Journal Citation Reports. It is indexed in Scopus, so Scimago shows its SJR quartile. ScholarsColab does not show a quartile until it can show the official one; the impact factor and rank above are calculated from open data.
Citations and papers per year
02Review time
Review time of Journal of Immunotherapy
Each paper took a different time. The green box holds the middle half of the papers and the dark line is the median; the whiskers reach the fastest 10% and the slowest 10%. Plan with the whole spread, not only the median.
Half of the research articles Journal of Immunotherapy published between Nov 2024 and Oct 2026 were accepted within 129 days of submission, and the middle half took between 79 and 180 days. This time includes peer review and any revision rounds. Papers that were rejected are not counted, because only published papers carry these dates.
In Oncology, Journal of Immunotherapy ranks 79 of 125 journals by review time (1 = fastest). See the fastest-review journals in Oncology →
03Fee waivers
APC waivers and discounts for Journal of Immunotherapy
Journal of Immunotherapy follows the waiver policy of its publisher, Wolters Kluwer (Lippincott): no general country waiver for Lippincott journals; most Medknow journals charge no APC. No country rule: the publisher decides case by case, or has no waiver scheme.
Waivers apply to fully open access journals. If Journal of Immunotherapy is a hybrid journal, you can publish without any fee through the subscription route.
Checking the waiver rules for your country…
Who funds research published in Journal of Immunotherapy
Funders named most often
A high share of funded papers usually means the journal is a common choice for grant-supported work in its field. If your funder pays article processing charges, or your country qualifies for a waiver, check what applies to your author team with the free APC waiver checker.
Submitting to Journal of Immunotherapy? See your rejection risk first.
Seven questions our reviewers ask in every audit, plus your abstract and the fit with this journal. Free, no sign-up, about 2 minutes.
04Indexing
Indexing of Journal of Immunotherapy
- ISSN
- 1524-9557
- eISSN
- 1537-4513
- Publisher
- Lippincott Williams & Wilkins
- Country
- United States
- Language
- English
- Web of Science categories
- Oncology, Immunology, Medicine, Research & Experimental
From the indexing lists used on ScholarsColab, updated 1 March 2026. Indexing can change: confirm on the Web of Science Master Journal List or the Scopus source list before submitting. Official Journal Impact Factors and JCR quartiles are published by Clarivate; the impact factor and quartile on this page are calculated from OpenAlex open data (see how the impact factor works).
05Reviewer comments
Reviewer comments and rejection reasons for Journal of Immunotherapy
No reviewer or editor comments have been shared for this journal yet. Did you submit here? Help other researchers by sharing the comments you received, anonymously.
Share reviewer comments for this journal →Across the reviewer comments researchers have shared with us, the points raised most often are figures, tables and equations (21%), literature and references (12%) and novelty and contribution (10%). Before you submit to Journal of Immunotherapy, a Manuscript Audit by a PhD reviewer in your area checks your paper against exactly these points.
Audit my paper before I submit →Not sure yet? Check if your paper is ready for this journal: free, no AI, under 5 secondsPreparing to submit here? Make sure reviewers don't stop at the issues they raise most often. A PhD reviewer in your area can audit your manuscript section by section, and we can convert it into the journal's LaTeX template.
06Journal Finder
Find the right journal for your paper
Is Journal of Immunotherapy right for your paper? Compare journals
Paste your title, keywords or abstract. See the journals that published the closest papers, with indexing, impact factor, review time and APC.
No AI or language model is used. Your words are matched against the titles of 156,503 real published journal papers, by our mentors and by other researchers (shown without names); journals are ranked by how many closely matching papers they published. Indexing comes from the SCIE, SSCI, AHCI, ESCI, Scopus and JCR 2024 lists, matched by journal name; the impact factor is calculated from OpenAlex open data, not the official Clarivate value, and no quartile is shown until the official JCR or SJR quartile can be; review time comes from the dates publishers deposit in Crossref (not every publisher deposits them). Always check a journal’s scope and current indexing before submitting.
07Questions
Frequently asked questions
How long is the review time of Journal of Immunotherapy?
Based on 33 research articles Journal of Immunotherapy published from Nov 2024 to Oct 2026, the median time from submission to acceptance was 129 days, and half of them were accepted between 79 and 180 days. After acceptance, papers appeared online after a median of 33 days. Source: received and accepted dates deposited by the publisher in Crossref, retrieved October 2026. Individual papers can take longer, especially with major revisions.
What is the impact factor of Journal of Immunotherapy?
Based on OpenAlex citation data (October 2026), the 2-year impact factor of Journal of Immunotherapy is 2.19: papers it published in the two previous years were cited 2.19 times on average in a year. The journal is listed in JCR 2024, so Clarivate also publishes an official Journal Impact Factor, which can differ.
What is the h-index of Journal of Immunotherapy?
The h-index of Journal of Immunotherapy is 124 (OpenAlex, October 2026): 124 of its papers have each been cited at least 124 times. Its i10-index is 1,644.
What is the quartile of Journal of Immunotherapy?
A journal's quartile (Q1 to Q4) is its position within a subject category: Q1 is the top quarter. The official quartiles are published by Clarivate in Journal Citation Reports (by Journal Impact Factor, in Web of Science categories) and by Scimago as the SJR quartile (in Scopus categories). Journal of Immunotherapy is listed in JCR 2024, so its JCR quartile is in Journal Citation Reports. It is indexed in Scopus, so Scimago shows its SJR quartile. ScholarsColab does not show a quartile until it can show the official one; the impact factor and rank above are calculated from open data.
Is Journal of Immunotherapy indexed in Scopus?
Yes. Journal of Immunotherapy appears in the Scopus list, according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
Is Journal of Immunotherapy an SCIE journal?
Yes. Journal of Immunotherapy is listed in the Science Citation Index Expanded (SCIE), according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
Is Journal of Immunotherapy in Journal Citation Reports (JCR)?
Yes. Journal of Immunotherapy is listed in JCR 2024, so it has a Journal Impact Factor. For the current impact factor and quartile, check Journal Citation Reports.
Does Journal of Immunotherapy offer an APC waiver?
Journal of Immunotherapy follows the policy of Wolters Kluwer (Lippincott): no general country waiver for Lippincott journals; most Medknow journals charge no APC. No country rule: the publisher decides case by case, or has no waiver scheme. Rules verified 27 October 2026; confirm on the publisher's page.
Who funds research published in Journal of Immunotherapy?
24% of 34 recent research articles in Journal of Immunotherapy name a funder in Crossref; the funders named most often are Hubei Province health and family planning scientific research project, Innovative Research Program of Xiangyang No.1 People’s Hospital, Hubei Provincial Natural Science Foundation of China.
Want a PhD expert to choose the journal with you?
Our Journal Selection & Submission service shortlists up to 5 journals that match your manuscript, indexing requirement and target quartile, and handles the submission. If your paper was rejected before, a Manuscript Audit shows what to fix first.
Not sure yet? Check your manuscript for this journal, free · How the process works
Popular journals
- The Lancet
- Nature
- Science
- PLoS ONE
- Scientific Reports
- Journal of the American Chemical Society
- Energy
- Analyst
- Materials
- Transplantation
- European journal of cancer
- Investigative Ophthalmology and Visual Science
- Construction and Building Materials
- Journal of Physical Chemistry A
- Food Chemistry
- Materials Science and Engineering: A
- Chemical Physics Letters
- Medical Physics
- Journal of Bacteriology
- Tetrahedron
Browse all journals: indexing, impact factor and reviewer comments →